4.5 Interaction with other medicinal products and other forms of interaction 
 No interaction studies have been performed. For the treatment of GPP flares, spesolimab is not expected to cause cytokine mediated CYP interaction as a perpetrator.Live vaccines should not be given concurrently with spesolimab (see section 4.4).There is limited experience from the use of spesol imab in combination with immunosuppressants in GPP patients (see section 4.4).
